(NPH.L) Neuropharm Group PLC Buy/Sell

RNS Number : 7995I Piper Jaffray Ltd 18 March 2010

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

1. KEY INFORMATION
Name of exempt principal trader Piper Jaffray Ltd.
Company dealt in Neuropharm Group plc
Class of relevant security to which the dealings being Ord 10p

disclosed relate(Note 1)
Date of dealing 17 March 2010
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long Short

Number Number
(%)
(%)
(1) Relevant securities 76,372
0.24%

(2) Derivatives (other than options) (3) Options and agreements to purchase/sell
Total 76,372
0.24%
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: Long Short

Number Number
(%)
(%)

(1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total

(c) Rights to subscribe (Note 2)

Class of relevant security: Details

3. DEALINGS (Note 3)
(a) Purchases and sales

Purchase/sale Number of securities Price per unit(Note 4)
Buy 15,000 10.50p
(b) Derivatives transactions (other than options)
Product name, Long/short(Note 5) Number of Price per unit(Note 4)
e.g. CFD securities(Note 6)

(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities Exercise Type, e.g. American, Expiry Option money
e.g. call option purchasing, varying to which the option price European etc. date paid/received per
etc. relates(Note 6) unit(Note 4)
(ii) Exercising

Product name, e.g. call option Number of securities Exercise price per
unit(Note 4)

(d) Other dealings (including new securities) (Note 3)

Nature of transaction(Note 7) Details Price per unit (if applicable)(Note

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 38.5(b) attached? (Note 8) NO
Date of disclosure 18 March 2010
Contact name Norman Gould
Telephone number 020 3142 8780

Name of offeree/offeror with which connected Neuropharm Group plc
Nature of connection(Note 9) Adviser and broker

Notes

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS The company news service from the London Stock Exchange

EMMUWAURRAAOAAR

RNS Number : 7187I Piper Jaffray Ltd 17 March 2010

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

1. KEY INFORMATION
Name of exempt principal trader Piper Jaffray Ltd.
Company dealt in Neuropharm Group plc
Class of relevant security to which the dealings being Ord 10p

disclosed relate(Note 1)
Date of dealing 16 March 2010
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long Short

Number Number
(%)
(%)
(1) Relevant securities 91,372
0.29%

(2) Derivatives (other than options) (3) Options and agreements to purchase/sell
Total 91,372
0.29%
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: Long Short

Number Number
(%)
(%)

(1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total

(c) Rights to subscribe (Note 2)

Class of relevant security: Details

3. DEALINGS (Note 3)
(a) Purchases and sales

Purchase/sale Number of securities Price per unit(Note 4)
Buy 27,730 10.50p
Buy 2,025 10.70p
(b) Derivatives transactions (other than options)
Product name, Long/short(Note 5) Number of Price per unit(Note 4)
e.g. CFD securities(Note 6)

(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities Exercise Type, e.g. American, Expiry Option money
e.g. call option purchasing, varying to which the option price European etc. date paid/received per
etc. relates(Note 6) unit(Note 4)
(ii) Exercising

Product name, e.g. call option Number of securities Exercise price per
unit(Note 4)

(d) Other dealings (including new securities) (Note 3)

Nature of transaction(Note 7) Details Price per unit (if applicable)(Note

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 38.5(b) attached? (Note 8) NO
Date of disclosure 17 March 2010
Contact name Norman Gould
Telephone number 020 3142 8780

Name of offeree/offeror with which connected Neuropharm Group plc
Nature of connection(Note 9) Adviser and broker

Notes

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS The company news service from the London Stock Exchange

EMMUBURRRRAOAAR

RNS Number : 5771I Piper Jaffray Ltd 15 March 2010

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

1. KEY INFORMATION
Name of exempt principal trader Piper Jaffray Ltd.
Company dealt in Neuropharm Group plc
Class of relevant security to which the dealings being Ord 10p

disclosed relate(Note 1)
Date of dealing 12 March 2010
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long Short

Number Number
(%)
(%)
(1) Relevant securities 121,127
0.38%

(2) Derivatives (other than options) (3) Options and agreements to purchase/sell
Total 121,127
0.38%
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: Long Short

Number Number
(%)
(%)

(1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total

(c) Rights to subscribe (Note 2)

Class of relevant security: Details

3. DEALINGS (Note 3)
(a) Purchases and sales

Purchase/sale Number of securities Price per unit(Note 4)
Buy 5,903 9.70p
Buy 3,475 10.70p
Sell 45,000 12.00p
(b) Derivatives transactions (other than options)
Product name, Long/short(Note 5) Number of Price per unit(Note 4)
e.g. CFD securities(Note 6)

(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities Exercise Type, e.g. American, Expiry Option money
e.g. call option purchasing, varying to which the option price European etc. date paid/received per
etc. relates(Note 6) unit(Note 4)
(ii) Exercising

Product name, e.g. call option Number of securities Exercise price per
unit(Note 4)

(d) Other dealings (including new securities) (Note 3)

Nature of transaction(Note 7) Details Price per unit (if applicable)(Note

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 38.5(b) attached? (Note 8) NO
Date of disclosure 15 March 2010
Contact name Norman Gould
Telephone number 020 3142 8780

Name of offeree/offeror with which connected Neuropharm Group plc
Nature of connection(Note 9) Adviser and broker

Notes

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS The company news service from the London Stock Exchange

EMMUVUARRVAOAAR

RNS Number : 5033I Piper Jaffray Ltd 12 March 2010

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

1. KEY INFORMATION
Name of exempt principal trader Piper Jaffray Ltd.
Company dealt in Neuropharm Group plc
Class of relevant security to which the dealings being Ord 10p

disclosed relate(Note 1)
Date of dealing 11 March 2010
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long Short

Number Number
(%)
(%)
(1) Relevant securities 85,505
0.27%

(2) Derivatives (other than options) (3) Options and agreements to purchase/sell
Total 85,505
0.27%
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: Long Short

Number Number
(%)
(%)

(1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total

(c) Rights to subscribe (Note 2)

Class of relevant security: Details

3. DEALINGS (Note 3)
(a) Purchases and sales

Purchase/sale Number of securities Price per unit(Note 4)
Buy 6,800 10.25p
Sell 11,000 11.50p
(b) Derivatives transactions (other than options)
Product name, Long/short(Note 5) Number of Price per unit(Note 4)
e.g. CFD securities(Note 6)

(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities Exercise Type, e.g. American, Expiry Option money
e.g. call option purchasing, varying to which the option price European etc. date paid/received per
etc. relates(Note 6) unit(Note 4)
(ii) Exercising

Product name, e.g. call option Number of securities Exercise price per
unit(Note 4)

(d) Other dealings (including new securities) (Note 3)

Nature of transaction(Note 7) Details Price per unit (if applicable)(Note

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 38.5(b) attached? (Note 8) NO
Date of disclosure 12 March 2010
Contact name Norman Gould
Telephone number 020 3142 8780

Name of offeree/offeror with which connected Neuropharm Group plc
Nature of connection(Note 9) Adviser and broker

Notes

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS The company news service from the London Stock Exchange

EMMUUVRRRWAOAAR